胸腺法新与2HRZE/4HR联合治疗肺结核对患者免疫细胞的影响研究

Study on the Effects of Thymalfasin Combined with 2HRZE/4HR on Immune Cells in Patients with Pulmonary Tuberculosis*

目的:探究胸腺法新与2HRZE/4HR联合治疗肺结核对患者免疫细胞的影响。方法:选取2022年1月至2023年1月江西省胸科医院收治的160例肺结核患者为研究对象,根据治疗方案不同分为观察组与对照组各80例。对照组采用2HRZE/4HR方案治疗,观察组在对照组基础上加用胸腺法新进行治疗。比较两组临床疗效、T淋巴细胞亚群、痰菌转阴率及不良反应。结果:观察组治疗总有效率为92.5%,高于对照组的87.5%,差异无统计学意义(P>0.05);治疗后,两组CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)均升高,且观察组高于对照组(P<0.05);治疗2个月后,两组痰菌转阴率比较,差异无统计学意义(P>0.05);治疗4个月、6个月后,观察组痰菌转阴率高于对照组(P<0.05);观察组不良反应发生率为8.75%,低于对照组的22.50%(χ^(2)=5.736,P=0.017)。结论:对肺结核患者采用胸腺法新联合2HRZE/4HR方案治疗,能极大地提高临床疗效,改善患者免疫功能,且不良反应较少。

Objective:To investigate the effects of thymalfasin combine with 2HRZE/4HR on immune cells in patients with pulmonary tuberculosis.Method:160 patients with pulmonary tuberculosis admitted to Jiangxi Chest Hospital from January 2022 to January 2023 were selected as the research subjects.According to different treatment plans,it were divided into an observation group and a control group,with 80 cases in each group.The control group was treated with the 2HRZE/4HR regimen,while the observation group was treated with thymalfasin in addition to the control group.Compared the clinical efficacy,T lymphocyte subsets,negative conversion rate of sputum bacterial,and adverse reactions between two groups.Result:The total effective rate of the observation group was 92.50%,which was higher than the control group's 87.5%,and the difference was not statistically significant(P>0.05).After treatment,the levels of CD3^(+),CD4^(+),CD8^(+)and CD4^(+)/CD8^(+)in both groups increased,and the observation group was higher than the control group(P<0.05).After 2 months of treatment,there was no significant difference in the negative conversion rate of sputum bacteria between the two groups(P>0.05).After 4 month and 6 month of treatment,the negative conversion rate of sputum bacteria in the observation group was higher than that in the control group(P<0.05).The incidence of adverse reactions in the observation group was 8.75%,lower than the 22.50%in the control group(χ^(2)=5.736,P=0.017).Conclusion:Thymalfasin combined with 2HRZE/4HR regimen for the treatment of pulmonary tuberculosis patients can greatly improve clinical efficacy and patient immune function,have fewer adverse reactions.